Orchard Therapeutics: CHMP Adopts Positive Opinion For Libmeldy - Quick Facts

(RTTNews) - Orchard Therapeutics (ORTX) announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending full, or standard, marketing authorization for Libmeldy, an investigational gene therapy for the treatment of metachromatic leukodystrophy. A final decision by the European Commission for Libmeldy is expected before the end of 2020.

Orchard Therapeutics noted that, if approved, Libmeldy would be the first commercial therapy and first gene therapy for eligible patients with early-onset Metachromatic Leukodystrophy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More